Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

VBH

- PMLiVE

Stemming the Flow–Medscape Presents at HLTH Europe

Medscape Education will be attending HLTH Europe from June 17-20. Be sure to drop by our booth to participate in our survey and enjoy exciting giveaways. Additionally, Dr. John Whyte,...

Medscape Education Global

- PMLiVE

How to hack a problem like healthcare

To create the most compelling clinical and cost-benefit arguments, the quickest and most comprehensive answers come by ‘bringing the outside in’ and treating the problem as a ‘hack’.

EatMoreFruit

- PMLiVE

Disconnected pharma: Navigating digital challenges and priorities in 2024

We are delighted to present Graphite’s research whitepaper for 2024 — and this year we are able to share the challenges and priorities that digital leaders are finding, in this...

Graphite Digital

- PMLiVE

Novartis shares positive late-stage results for Fabhalta in rare kidney disease C3 glomerulopathy

Approximately one to two people per million worldwide are diagnosed with C3G every year

- PMLiVE

Novartis and PeptiDream expand peptide discovery collaboration in deal worth over $2.8bn

The agreement builds on the companies’ peptide-drug conjugate collaboration announced in 2019

- PMLiVE

Kathy O’Connell joins Research Partnership as Senior Vice President, Business Development

Kathy has been working in the pharmaceutical market research industry for over 25 years. She has a diverse business background, with in-depth experience in progressively responsible sales, business development and...

Research Partnership

- PMLiVE

Novartis’ Lutathera receives FDA approval to treat neuroendocrine tumours in paediatric patients

The incidence of neuroendocrine tumours has increased over the past several decades

- PMLiVE

Novartis’ targeted combination therapy recommended by NICE to treat childhood brain tumours

Gliomas are the most common type of brain cancer in paediatric patients

- PMLiVE

Novartis presents positive long-term data for relapsing MS treatment Kesimpta

Approximately 85% of MS patients are initially diagnosed with relapsing forms of the neurological disease

- PMLiVE

Novartis shares positive late-stage results for Fabhalta in rare kidney disease IgA nephropathy

Approximately 25 people per million worldwide are diagnosed with IgAN every year

- PMLiVE

Novartis’ blood cancer therapy Kymriah recommended by NICE for routine NHS use

In England, ALL is responsible for around 300 new diagnoses every year in people aged 25 years and under

- PMLiVE

Getting Past the Old-Fashioned View of Patient Advocacy

Patient advocacy organizations today are data-driven, doing amazing work — and have the hard evidence to support their impact on patient care. The challenge is getting past the perception of...

Medscape Education Global

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links